Uses
TissueBlue 0.025% is indicated to selectively stain the internal limiting membrane (ILM). TissueBlue 0.025% is a disclosing agent indicated to selectively stain the internal limiting membrane (ILM).
Source: US FDA prescribing information
Molecule
Brilliant blue g
Disclosing Agent
Available on requestOrphan
- Presentations
- 1
- Brands
- 1
- Manufacturers
- 1
- Available from stock
- 0
Brilliant blue g is a disclosing agent indicated to selectively stain the internal limiting membrane (ILM). It is available as injection for intraocular and ophthalmic use. MedsAcross supplies Brilliant blue g for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- Pharmacological class
- Disclosing Agent, Dyes
- US FDA first approval
- 20 December 2019
- EU status
- Not recorded
- Orphan designation
- Yes
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Intraocular, Ophthalmic
- Dosage forms
- Injection
- Identifiers
- UNII M1ZRX790SICAS 6104-58-1DrugBank DB15594Q72436062
Clinical information
From the regulator-approved product information. Each section names its source.
How it works
Brilliant Blue G has been shown to selectively stain the ILM, but not the epiretinal membrane nor the retina, making it easier to visualize the membrane for removal, although the exact mechanism of this selectivity has not been elucidated.
Source: US FDA prescribing information
Dosing overview
TissueBlue 0.025% is carefully injected into the Balanced Salt Solution (BSS)-filled vitreous cavity using a blunt cannula attached to the pre-filled syringe, without allowing the cannula to contact the retina or allowing TissueBlue to get under the retina. Sufficient staining is expected within a few seconds. Following staining, all excess dye should be removed from the vitreous cavity. Inject TissueBlue 0.025% directly in a Balanced Salt Solution (BSS)-filled vitreous cavity. Excess TissueBlue should be removed from the vitreous cavity.
Source: US FDA prescribing information
Contraindications
None None
Source: US FDA prescribing information
Warnings and precautions
Excessive Staining Excess TissueBlue 0.025% should be removed from the eye immediately after staining. Use of the Syringe Make sure the plunger moves smoothly before injecting the solution. Do not use the product if the plunger does not move smoothly to prime the cannula.
Source: US FDA prescribing information
Side effects
Adverse reactions that have been reported in procedures that included the use of Brilliant Blue G Ophthalmic Solution have often been associated with the surgical procedure. These complications include retinal (retinal break, tear, hemorrhage, and detachment) and cataracts. Adverse reactions that have been reported in procedures that included the use of TissueBlue 0.025% have often been associated with the surgical procedure. The complications include retinal (retinal break, tear, hemorrhage, and detachment and cataracts.
Source: US FDA prescribing information
Storage
TissueBlue 0.025% should be stored at 15°C to 25°C (59°F to 77°F). Protect from light, frost and moisture.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
1 presentations of Brilliant blue g, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Tissueblue 0.0125 mg/0.5 mL injectionIntraocular, ophthalmic | DORC Dutch Ophthalmic Research Center (International) | US FDA | Available on request |
Brands by market
1 brand names across 1 markets.
United States
Manufacturers
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 20 December 2019 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Questions and answers
Is Brilliant blue g available for export from India?
Yes, on request. MedsAcross lists 1 presentations of Brilliant blue g and sources them for licensed hospitals, importers and physicians against valid import documents.
What brand names does Brilliant blue g have?
The catalogue lists 1 brand names for Brilliant blue g, including Tissueblue.
Is Brilliant blue g approved by the US FDA?
Yes. The US FDA first approved Brilliant blue g on 20 December 2019, according to Drugs@FDA.
Does Brilliant blue g need cold chain shipping?
No listed presentation of Brilliant blue g is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
References
- TISSUEBLUE prescribing information (DORC Dutch Ophthalmic Research Center (International)). U.S. National Library of Medicine, DailyMed. Retrieved 17 April 2026
Request Brilliant blue g for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.